BOULDER, Colo., Oct. 25, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2017 and hold a conference call to discuss those results on Tuesday, November 1, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
Date: | Tuesday, November 1, 2016 |
Time: | 9:00 a.m. Eastern Time |
Toll-Free: | (844) 464-3927 |
Toll: | (765) 507-2598 |
Pass Code: | 93600421 |
Webcast, including Replay and Conference Call Slides:
http://edge.media-server.com/m/p/8qcss7h2
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca).
CONTACT: | Tricia Haugeto |
Array BioPharma Inc. | |
(303) 386-1193 | |
Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2017-on-november-1-2016-300350249.html
SOURCE Array BioPharma Inc.
